Hexo Corporation (NASDAQ:HEXO) Q3 2020 Earnings Conference Call June 11, 2020 8:30 AM ET
Sebastien St-Louis - Chief Executive Officer
Steve Burwash - Chief Financial Officer
Jennifer Smith - Director, Investor Relations
Conference Call Participants
Aaron Grey - Alliance Global Partners
Tamy Chen - BMO Capital Markets
John Zamparo - CIBC
Rupesh Parikh - Oppenheimer
Graeme Kreindler - Eight Capital
Scott Fortune - Roth Capital Partners
Andrew Carter - Stifel
Matt Bottomley - Canaccord
David Kideckel - AltaCorp Capital
Douglas Miehm - RBC Capital Markets
Pablo Zuanic - Cantor Fitzgerald
John Chu - Desjardins
Ladies and gentlemen, thank you for standing by and welcome to the Hexo Q3 2020 quarterly call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question and answer session. To ask a question during this session, you will need to press star, one on your telephone keypad. Please be advised that today’s conference is being recorded. If you require any further assistance, please press star, zero. Thank you.
I would now like to hand the conference over to your moderator for today, Jennifer Smith, Director of Investor Relations. Please go ahead.
Good morning. Thank you all for joining us this morning for our 2020 Q3 earnings call. We will start with a presentation by our CEO, Sebastien St-Louis, followed by a recap of our third quarter results by our CFO, Steven Burwash, before opening the floor to questions from our financial analysts.
Before we begin, we would like to remind you that today’s presentation contains forward-looking statements that involve known and unknown risks and uncertainties and other factors that could cause actual events to differ materially from current expectations. The forward-looking statements are based upon and include the company’s current internal estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Any statements contained herein or discussed during this session that are not statements of historical facts may be deemed to be forward-looking statements. Such statements can often but not always be identified by use of forward-looking terminology and other similar words and expressions that are predictions or indicate future events and future trends, including negative and grammatical variations thereof, or statements that certain events or conditions may or will happen, or by discussions of strategy. These statements should not be read as assurances of future performance or results.
Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Those risks and uncertainties include, but are not limited to those relating to the company’s ability to execute its business plan, renew required permits, licenses, and related regulatory compliance matters, implement its growth strategy, obtain and maintain financing on acceptable terms, maintain and renew required licenses, maintain good business relationships with its customers, distributors and other strategic partners, keep pace with changing consumer preferences, protect intellectual property, manage and integrate acquisitions, retain key personnel, and relating to the company’s competitive advantages, the development of new products and product formats for the company’s products, changes in laws and regulations, and the absence of materially adverse changes in the industry or global economy.
A more complete discussion of the risks and uncertainties facing the company appear in the company’s annual information form and company’s Management Discussion and Analysis for the three and nine-month periods ending April 30, 2020 which are available under the company’s profile on SEDAR.
Although the company has based forward-looking statements on assumptions that it believes are reasonable, it cautions the readers that the actual results and developments, including the company's results of operations, financial condition, liquidity, and development of the industry in which the company operates may differ materially from those made or suggested by the forward-looking information contained herein.
A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. The company disclaims any intention or obligation except to the extent required by law to update and revise any forward-looking statements as a result of new information or future events, or for any reason. Any forward-looking statement contained herein or discussed during today's session is expressively qualified in its entirety by the above cautionary statement.
I'll now turn the floor over to Sebastien.
Thank you Jennifer, and good morning everybody. I’d like to start by wishing everybody a safe time and good health, and to thank and acknowledge the incredible efforts and dedication of our entire team at Hexo as we navigate through this pandemic caused by COVID-19. While the global economy has seen a dramatic reduction in GDP and staggering unemployment numbers, what’s encouraging, at least in our industry, is that we’ve been stable, and even more than stable, we’re growing.
Our team has rallied to meet the challenges as presented and actually exceeded expectations. We’ve continued to introduce new products and we continue to increase our volumes as we gain market share on our competitors. The company has implemented rigorous safety protocols to mitigate the potential exposure and provide a safer work environment as possible to all our employees. Our team members have demonstrated incredible resolve to ensure we continue to execute at the highest levels and achieve operational excellence. We remain vigilant and we’ll continue to proceed with caution.
While we continue to operate during the pandemic, we continue to be cautious about future expectations. Our plans to achieve adjusted EBITDA positive in the first half of fiscal 2021 or the end of the calendar year will depend on the growth of retail stores in our two largest markets, Ontario and Quebec. It’s difficult to determine the timing of new licenses for new retail stores in Ontario and the build-out of additional stores in Quebec, but we’re very encouraged by the huge progress that both our provincial partners have made.
With only a limited number of physical stores, the revenue numbers that were published this week by SQDC and OCS demonstrates the tremendous potential of both markets. SQDC reported sales of 47 tons of product and profits of $26 million with less than 50 stores. I want to congratulate SQDC and Jean-François Bergeron on tremendous results, and we’re very proud to remain their preferred partner, and for our participation in Quebec’s success. On the Ontario side, we’re super encouraged by the amazing work that Cal and his team have done on analytics and providing the market with detailed market share analysis by product, and we look forward to continuing to see more.
Our industry continues to grow during the pandemic, and that’s a testament to the consumer demand for safe and legal product offered by licensed producers. Statistics Canada reported that sales reached $181 million in the month of March, and we’re seeing steady demand in the months that have followed. While the March figures only lead to an annual run rate of approximately $2.2 billion, most studies have reported that the true market in Canada is closer to $7 billion to $10 billion annually.
There is a great deal of work to be done by licensed producers and governments at each level to safely provide all our products to consumers, the products that consumers are clearly demanding to be able to get to the full potential of this legal market. We need the governments to either continue to build the retail infrastructure or allow the private sector to provide the service the consumer demands. The licensed producers need to lead the way forward by creating and delivering products that compete effectively with the illicit market.
At Hexo, we’re determined to be leaders in adult-use market in Canada and other legal markets where we play. Our philosophy is to go a mile deep instead of a mile wide in each market that we participate in and with each product that we launch. It was this approach that led us to negotiate a significant preferred supplier agreement with the Province of Quebec. We wanted to be the dominant player and achieve leading market share. We’ve done that. We’ve maintained a market share north of 30%, and we continue to provide outstanding service to this prized market, and at this point with the new success we’ve had operationally, we’re poised to expand nationally and to start to provide that same level of service in other markets.
There’s other examples of how this approach of going narrow and deep has led to successful outcomes for Hexo. We led the way in creating the 28-gram package format and pricing it to compete directly with illicit market. Our competitors have followed suit, but we’ve achieved strong market share with Original Stash. We’ve been selective in our launch of 2.0 products and our Hash product has been an overwhelming success. We’ve established a dominant position with this product category.
I’m very pleased to share that our Belleville facility is now fully licensed, which includes the Truss beverage facility. This state-of-the-art facility is highly automated, it’s ideally located to serve both largest markets in Canada and has a national scale. It has the capacity to grow along with our business and our partners. The key effect of this facility is it is shifting Hexo to a true manufacturing company while keeping our roots in agriculture in Gatineau and Masson.
We were one of the first companies to partner with a Fortune 500 company. We created the Truss joint venture, our joint venture with Molson Coors, and this company will launch a series of products from a newly constructed state-of-the-art bottling and canning operation at the Belleville site, and it should lead to being one of the very few players in Canada with significant market share in the cannabis beverage market.
We’ve also expanded our partnership with Molson Coors with the creation of Truss USA. As per our philosophy, we’re going to focus on a first market to dominate in Colorado and to test and learn.
During the latter half of 2019, it became clear that the capital market environment for cannabis companies had changed. Access to capital was going to be much more restricted. Hexo led the way by being one of the first companies to rationalize our operations. This was also significantly impacted with the slow rollout of Canadian retail infrastructure, but we adapted very quickly. We were leaders in the following meaningful ways: we’ve provided exceptional service to the Province of Quebec, we moved up the ladder in market share, and as you know I’ve often stated our goal is to become a top two player in adult use market share in Canada. Hexo has moved quarter-over-quarter from a top five spot to now the top four spot nationally.
We’ve cultivated new high THC strains that are clearly in demand from the consumer. We have some new Hexo Plus products in market now achieving 26% THC. We’ve stabilized and improved our gross margins, being ahead of plan by delivering 40% this quarter. This has allowed us to launch and lead the path in the value segment without our margin deteriorating. We’ve reduced cash operating expenses to achieve our internal targets, and we’ve done all of that in less than 12 months, a big thanks to the team.
We’ve also created products that utilize all the components of our cultivation efforts so that inventory does not grow excessively and consume our cash flow. Hexo is making substantial progress towards the trim problem that we all face in this industry. Our inventory impairment has been minimized, and we’ll continue to monitor going forward.
We have a lot of work to do at Hexo, but the good news is that our revenues are growing, our yields and volumes sold have improved, our gross margin has increased, and our costs are coming down. Our adjusted EBITDA loss is under $5 million and we hope to be EBITDA positive this year. We’ve achieved all that while moving up the ladder in market share and taking the top four national adult-use share spot.
With a series of financings we’ve completed since the end of the last calendar year, our business is on solid financial footing. We look forward to building on those strengths.
Steve, I’ll turn it over to you to speak about our financials.
Thanks very much, Sebastien. Good morning everybody.
As Sebastien mentioned, Q3 demonstrated significant improvement in a number of different ways as we move closer to our goal of becoming adjusted EBITDA positive. On the revenue front, revenue from sales in the quarter increased by $7.1 million or 30% to $30.1 million from $23.8 million in Q2 Total revenue from sales in the quarter increased by $15 million or 94% when compared to the third quarter of the previous year.
Net revenue increased to $22.1 million from $17 million in Q2 and from $13 million in Q3 2019. Gross revenue from the adult use channel was $29.8 million, and that represents an increase of 30% from the previous quarter two sales of $23 million. Gross adult use sales also increased by 104% when compared to the same period in 2019.
Our value brand, Original Stash continues to drive our sales with 48% increase from the previous quarter. Sales of this product were introduced in the Province of Saskatchewan as our channels continue to grow. The increased sales of Original Stash also contributed to the reduced price per gram before excise tax, which fell by 9% to $3.19 from $3.49 during the period. Newly launched Hash in the quarter comprised approximately 19% of overall sales quarter-over-quarter. Similarly, oil extract drops contributed 7% to overall adult use sales growth. Adult use volumes sold in the period increased 42% to 9.3 tons compared to 6.6 tons in Q2. Sales volume in the third quarter of fiscal 2020 increased 238% from 2.8 tons equivalent sold in the same quarter of fiscal 2019.
Cost of sales for the quarter were $13.4 million compared with $11.3 million in the previous quarter, representing an 18% increase. The increase is the result of the increased sales in the period offset by realized benefits of reduced direct and indirect labor. Some of the factors that contributed to the labor costs decreasing were COVID-19, which allowed for reduced labor inputs to our cost per gram, and also activity in our Belleville facility for packaging. The cost of goods sold for the third quarter of last year were $6.6 million. The 100% increase in COGS is trending with the 94% increase in sales.
Gross margin before fair value adjustments for Q3 2020 was $8.8 million or 40% compared with net revenues from the sale of goods, compared to $5.7 million or 33% in the prior quarter. This increase was due to the reduction in the cost per gram as a result of decreased packaging and irradiation costs, as well as the improved yield per square foot. While we expect there to be fluctuations to our quarterly gross margin as we ramp our activities in Belleville and introduce new products over the next few quarters, we view this as a significant indication that we will be able to achieve the long-term sustainable portfolio-wide margins of 40% that we’ve targeted. Gross margin after fair value adjustments and impairments was $5.7 million compared with negative $7.9 million in Q2.
Our operating expenses continued to decrease through the quarter to $26.8 million from $281.5 million in Q2. Now, remember Q2 included a large number of non-recurring expenses that came about as a result of changes in the conditions of the Canadian market. For that reason, we look at our operating expenses in two segments: core and non-recurring. For our core operating expenses, we saw a decrease of approximately 9% to $25.7 million in Q3 from $28.1 million in Q2. This was down from our peak amount of $46.9 million in Q4 2019. We have continued to focus on reducing expenses where possible and ensuring that each dollar we spend is put to its best possible use.
G&A decreased to $11.2 million from $14.5 million in Q2 2020 due to reduced consulting and professional fees, IT, and insurance costs. Marketing and promotion increased to $2.1 million from $400,000 in Q2. As mentioned last quarter, the Q2 expenses were reduced by the reversal of an over-accrual. The current spending is more in line with future expectations. Research and development decreased to $1 million from $1.2 million as a result of reduction in headcount and consulting fees.
Now a quick look at the non-recurring expenses we saw: an additional $865,000 in restructuring costs related to the continued right-sizing of the team. We’ve continued to focus in ensuring that we have our teams properly staffed with the correct number of people sharing the workload and are appropriately rewarding those top performers who are helping us to achieve our goals. We also had a loss on disposal of assets to do with the equipment that has been sold out of our Niagara facility. That number was $3.2 million.
Loss from operations of $21.1 million in Q3 compared to $289.4 million loss in Q2 2020. If we normalize the operating loss and exclude certain non-cash and non-recurring items, this decreased to $20.7 million compared with $23.2 million in the prior quarter. The decrease in loss is primarily related to an increase in gross margin and a decrease in operating expenses.
We remain focused on becoming adjusted EBITDA positive. We are focused on driving revenues as a market leader in the markets we serve and reducing expenses through operational excellence.
We ended the quarter with $95.3 million in cash, cash equivalents and short-term investments. Subsequent to the end of the quarter, we closed an additional financing which added over $50 million to our balance sheet. After a reassessment of our capital plans, we have reduced our requirements dramatically and expect to incur the majority of expenditures in capital over the next three quarters. With the reductions, realignments and operational changes we’ve made, our recent financial raises and the strategic use of our ATM will allow us to fund our Canadian operations.
I’ll now turn the call back over to Jennifer.
Thank you Steve. We will now take questions from our analysts. Due to the large number of analysts joining us today, I would ask you to limit your questions to two at a time. You’re welcome to re-join the queue after that. Thank you.
Aaron Grey with Alliance Global Partners, your line is open.
Hi, good morning, and congrats on the quarter.
Thanks Aaron, good morning.
I guess my first question would go along with receipt of the license at the Belleville facility. I know that you guys had been waiting for that, and there’s a lot of things that could come along with it, so I just wanted to get some further color on what you expect in terms of the top line profile, the shift from more automated packaging, and how that can flow through to the top line, the timing of that.
Then also on the top line, I know you kind of gave some color in terms of it being dependent on whether or not you can get more brick and mortar stores in Ontario and Quebec, but how also do you feel like the Belleville facility licensing helps you to expand market share in some other provinces outside of the two main ones you have right now? Thank you.
Thanks Aaron. Super excited about Belleville getting its full licensing now, so fully operational facility. The first thing - short term, slight negative on gross margin. I remember that now, but that’s an operating asset that we’re going to take an amortization hit, so that will show up next quarter, so I expect a little bit of pressure on gross margin.
Now, medium term, what’s super exciting is that the efficiencies that Belleville is bringing to the table just completely make up for that and more. We’ve got automated packaging going in, a substantial reduction of labor through productivity, the COGS are going to continue to go down, and that’s just on direct cost savings. The most significant thing is touching on the market share increase that you’re alluding to and what Belleville is going to do there by creating new products.
And so, with the capacity that we have for Belleville, the single most important impact to Hexo is that it’s allowing us to create more 2.0 products, convert more of our trim that’s on our balance sheet into sellable products at till sales, which results in more products on the shelf and more diversity for consumers. So, we’ve already started to see that and looking forward to rolling out the full suite of products over the coming quarters.
All right, great. Looking forward to see those kind of come out. My second question, just continuing on with 2.0 products, now you do have Belleville rolled out, you’ve come out with Hash, which seems to be off to a great start. Help us think about those additional 2.0 products coming online and kind of impacting the sales line there, and any color you could give in terms of what you’re seeing right now in the marketplace from 2.0 products that have come out from some of your peers and competitors, and where you think the opportunity is for Hexo to come in when it comes out with its own products. Thank you.
Well, really happy. I mean Hexo for years has been first to market with a lot of product categories. We recently defined the 28-gram. We’re now being first with a hash offering that’s national, so we know those things work, so we’re doubling down. Getting leaner on existing product lines, so that we can keep upping the quality. Our Original Stash product now has better humidity and better THC than we’ve ever seen in it, and so really happy to be able to continue to offer pricing that beats the black market with a better quality.
But now as well with the success of Hash, we’re starting to look at other categories, so look to us continue to expand on our pre-roll line, our vape line, make sure those work well, and perhaps even more importantly celebrating the launch of our beverages with Truss. So, we’re super excited to have received the Truss license, so in the next short while, we’re going to be coming out to market with a full portfolio of Truss-branded products, super exciting, ready-to-drink beverages.
We’re already in market with some ready-to-drink beverage drops, so our Veryvell drops are available today. They are phenomenal - I mean, you can add a couple drops to any flavored drink and it turns any drink, whatever you prefer, into a cannabis drink, and you can customize the formulation. So, those have been a great success as well, so we’re going to double down on those. Of course, we’re keeping a couple surprises for consumers downstream, so you’ll have to wait for those.
All right, great. Thanks. I’ll hop back in the queue.
Tamy Chen with BMO Capital Markets, your line is open.
Thanks, good morning everyone. First question is, Sebastien, I was wondering if you could speak a bit more to what industry and maybe your sales trends are looking like now. There was a lot of noise with the COVID pantry loading in March. Have things now settled back to pre-COVID levels, and any color among the different provinces would be helpful as well.
Yes, I think what has been--and again, I commended OCS on their report. I think more of that will be super useful. I think that gives great clarity on what’s happening in our industry. We continue to grow.
Yes, we had a little bit of noise around pantry loading for COVID. I think sales of cannabis just continued to go up. We are in a growth category, there’s no doubt in my mind. Yes, we have to keep working through logistical challenges, but no sign of slowing down here at Hexo, so quite happy with how we’re proceeding.
That being said, there is a lot of pricing pressure in the next year as we have very fierce competition, and getting to that top two spot is a very difficult journey while assuring profitability, so we have a hard task ahead of us but I’m sure the team will deliver.
Got it, okay. That’s helpful. As you mentioned the pricing pressure, so that was going to be my next question. You’ve talked about what to anticipate about the Belleville ramp in the near term on the gross margin hit, but I wanted to get your thoughts on as you think about this competition in the industry, especially in value, do you anticipate or do you think you might need to get more competitive on the pricing profile of your Original Stash going forward? When you think about the potential gross margin volatility at minimum from the Belleville ramp, I mean are there still levers in your opex for you to reduce to achieve that positive EBITDA over the next quarter or two? Thanks.
Thanks Tamy. Yes, so Original Stash, really interesting case study I think. We launched Original Stash as a black market killer. It was not launched as a value brand, it was really launched as a way for us to offer consumers something legally controlled, better quality at the same price as what they already pay. What happened is from a legal market perspective, the positioning and pricing were just so aggressive - I mean, we were 40% better priced than almost all our competitors, so it really forced a shift of the entire legal market down.
What I think is going to happen is you’re going to see an ecosystem created around Original Stash with some value products that will come out below Original Stash. The reason I’m separately the two, the quality of Original Stash is just phenomenal. The humidity control is bang-on, the THC percentages are amongst the highest in the country, and so it’s a very, very high quality product. I think there’s definitely room for true value plays below that.
Hexo is not in a rush for the race to the bottom in terms of that category. Also, given that our greenhouse asset is producing such high quality product, I think we have a lot of opportunity for actually higher quality product. We’ve just launched Hexo Plus in Quebec, so that’s been quite a success with 26% THC product, so more care and attention there.
I think the whole market is going to shift down. Original Stash is going to take its place as a midmarket black market killer, with value bargain basement, call it 10 to 15% THC products below that at a better pricing, and I think Hexo still has a ton of opportunity in both growing Original Stash market share and introducing new premium products.
On the opex versus COGS question, opex is starting to get very lean for what we want to build. Remember that I’m set out over the next 10 years to build a global top player with Hexo, so that means I need significant executive bench strength, and we have that today. We have a phenomenal team, we’ve added food, CPG experience, GMs at every site, and so those people are critical to the success of the organization. A little bit of rounding around the edges on opex, but the COGS opportunity and what Belleville is going to deliver is still tremendous, so I’m really not worried about the pricing pressure.
Got it, thank you.
John Zamparo with CIBC, your line is open.
Thanks, good morning. My question is also around the value segment and competition more broadly. With net pricing down around $2.25 a gram this quarter, I’m just wondering, do you think this is a floor for Hexo pricing? I know the prior comment maybe was more around the industry being into a deep value category, but do you see like-for-like pricing on Hexo products seeing a floor here, or do you think there’s more room for that to decline given it does seem that you were early to the category for value, but some competitors seem to be chasing that as well?
Yes John, let them chase. I invite them to chase. At the end of the day, the consumer will drive pricing, and I don’t think the consumer has a floor in mind, so as we continue to achieve efficiencies and the whole industry, including Hexo, is still in its infancy. Now, we’ve done very well, we’re one of the lowest cost producers all-in in the whole country, and you can see that in our gross margin and reflected in our pricing.
But if you look at what we shipped in the quarter, over 9 tons of product. If you look at our market share by volume, Hexo is a top player - like, forget top four, and I won’t specify exactly which competitor I’m against, but we’re right up there as one of the top players, so let the price shock settle and you will see Hexo emerge, I think, in that top two scenario.
If we need to continue to use our cost advantage to lower pricing to ensure we stay in that top two spot, we will do so; but I don’t think of this thing in terms of a pricing floor because Hexo doesn’t need a pricing floor. We still have so much upside on COGS control with our Belleville facility that we will continue to deliver better quality to consumers at better prices for at least the next few years.
Okay, that’s helpful. Thanks. My second question is on the capital contributions required for Truss and for the U.S. JV. I know these are billed as being generally capital light - I think it’s around $30 million in contributions this year. Just trying to get a sense of how much more is necessary to fund that project, at least given your current game plan. I know it can expand in future years, but given what you’re trying to do now, how much more do you think you’ll have to contribute to the JV?
Yes, we learned so much from Molson Coors, and the U.S. execs are absolutely phenomenal in approaching a capital light model, so it’s really exciting. But what we did in Colorado is we took all the lessons learned from Truss Canada, which had a significant investment, right - you’re talking about $90 million, about 42% which was Hexo and the balance was Molson, in Canada to build this world-class asset. But on the Hexo side, we’ve been innovating, we’ve been building a patent portfolio on emulsions, etc. We can take all that IP, we’re moving it down to Colorado. The regulatory environment in Colorado allows us to use pre-existing Molson Coors assets for distribution, and so what’s really exciting is we’re using installed capacity to be able to distribute in that market.
Capital call is in great shape. For now, the strategic plan at Truss and Truss USA is fully funded. I do expect that as we prove out the Colorado market, we will want to expand further, regulations permitting of course, and making sure we stay onside with the FDA as we’ve done so far. I expect at that time we will be presented with more capital deployment opportunities.
Okay, understood. Thank you very much.
Rupesh Parikh with Oppenheimer, your line is open.
Good morning. Thanks for taking my questions. Just going back to your commentary about hoping to achieve positive adjusted EBITDA in the first half of fiscal 2021, as you look at Ontario and Quebec, how many stores are there today and what level do you think you need to see to get to positive EBITDA?
Rupesh, I think that given our market right now, we have decoupled ourselves a little bit from store openings in terms of being able to push forward. Our positive EBITDA is going to come through incremental market share gains out of the existing stores, so I don’t think it’s fair for me to say we’re counting on our provincial partners to open X-stores in terms of us to achieve that. I think we’re going to achieve adjusted EBITDA no matter the store count. The story obviously gets better if our partners open more stores, which they’re doing, so we’ll just keep an eye on that.
Okay, and then just a second follow-up question, you look at your portfolio, a lot of progress on the value side. Are you happy with your portfolio position and where you are from an inventory perspective?
No. I’ll be happy when the inventory coming off the line goes right to the till and gets sold in two weeks, and everything is fresh with nothing older than three days. So no, absolutely not happy. With that said, the progress we’ve made has been absolutely fantastic, and as I mentioned, most of our product on the shelf now is less than a few weeks fresh, so we’re talking a massive improvement from early days of legalization. Way better quality for the consumer, so that I’m thrilled with.
Okay, great. Thank you.
Graeme Kreindler with Eight Capital, your line is open.
Hi, good morning, and thank you for taking my questions here. Sebastien, I wanted to go back and explore a little deeper your comments about the positioning of Original Stash. I understand the distinction you made between it being a black market buster versus a value segment, but do you think there is a risk of the overall consumer just grouping all of the offerings, and that offering has also increased in competition, as value and you could potentially see another iteration of what we’ve seen on some of the mid-grade products, where consumers end up just differentiating on price as opposed to brand, or price in terms of dollar to percent THC? Are you worried at all, to put it another way, that increased competition on the lower bound of that segment could actually erode Original Stash’s position or is the pie of this market going to be grow substantially enough, where it ends up being a smaller slice but of a much bigger pie? Thank you.
Yes, so it’s twofold, and there’s a bit of a third part to it. With Original Stash, the whole market is going to shift down. There’s pricing pressure across the board, right? As companies lived efficiencies, our provincial partners are certainly remaining very competitive, forcing the best possible product for their consumers at the best price. Nobody is going to get away with just continuously reducing their costs but not flowing that through to the consumer. That’s one piece.
The other piece is most of the competitors in the country don’t have manufacturing assets of the sophistication as what Hexo has at our Belleville facility, so I don’t think that the existing 300 licensed producer system is going to continue going the way it does. It’s simply impossible for a small scale producer with no manufacturing capacity to compete with a company like Hexo, so I think that will continue to mean meaningful improvement for the consumer.
The third part of that is as we continue to see yield improvements at our cultivation center, because it’s not just from a manufacturing perspective we’re making progress, as we continue to put out more product, Hexo also has some opportunities in introducing new brands that are positioned at a better value than Original Stash, so we’re really starting to look at that sector as a total growth opportunity while seeing Original Stash as growth.
But yes, you’re entirely right to say that what we’ve launched basically defined the market. I mean, we had 11 of our competitors follow in the four to six months after we launched, but Hexo is not new to that. The same thing happened when we did Elixir a couple years ago and I expect that to be the theme for the coming years, but if I’m always six months ahead of everybody, I think that’s going to be good for Hexo.
Okay, thank you for that. I appreciate the color there. That’s helpful. Just as a follow-up to that, could you share with us what the total percentage of Original Stash sales were of the 9.3 tons sold in the quarter, and what the specific gross margin on Original Stash sales was?
Original Stash was about half, if we give you round numbers in terms of volume, and in terms of margin, we don’t share by product, but I can tell you obviously we’re targeting that 40% portfolio. The great thing this quarter is I don’t need even to talk about targeting, because we achieved it, so 40% gross margin across the board.
Okay, thank you very much for that.
Scott Fortune with Roth Capital Partners, your line is open.
Good morning, thanks for the call. Can you provide a little more color outside Quebec? I know you’re maintaining 30%-plus market share there. What about the other provinces and gaining market share with your products in the other provinces moving forward here?
Yes, absolutely. We’re going market by market, right, so we’re being selective. The idea is not to be the number one player in every single market in Canada. The idea is to assure that we’re top two in the markets in which we operate, so we’re rolling that out. Obviously staying close to our friends in Ontario, that’s a very large market, but also active in the Maritimes and out west, so we’re looking at the major markets. We’ve started to roll out 2.0. Our full portfolio is products is being made more and more available. We just appointed a new SVP of sales, super excited to have them start building up our presence outside of Quebec, and look forward to building share there.
Okay, and then a follow on, we know as Canada got legalized, the flower, the inventory kind of ramped up from that standpoint. The provinces are taking a little more cautious approach on the 2.0 product from that standpoint. How are they viewing kind of orders, reorders for 2.0 from that standpoint, and then what are the discussions around the potential beverages as you roll that out down the road here?
Yes, our beverage portfolio has just had an absolutely resounding success. We’re taking that portfolio approach, basically going to the distributors and saying, we have your one-stop beverage solution, right? You can deal with one or two suppliers, but one of them is going to be Hexo and you can have a complete beverage offering, so that’s really resonating as we’re touching north of 80% of consumer occasions with our beverages, so we’re not short on orders. We were very happy to see that full license in Belleville so that we could get going on ready to drink. We have a number of fridges in a lot of retailers as well, so we’ll be able to offer cold drinks to consumers, so that’s all part of the Hexo promise of quality.
Sorry, the first part of your question again?
How you’re seeing the reordering of 2.0 products. I know there’s a conservative [indiscernible] inventory too much there. How do we look at acceleration there since?
Yes, so the reorders--really, the provinces, what they’re doing isn’t complicated, right? They’re reordering what sells at the till, so we’ve put boots on the ground to really understand what the till sales are. We’re looking at the velocity rates and we’re being very careful to keep the channel lean. Our goal is to get to just-in-time system, where something comes off the line, gets produced, goes into store - maximize freshness, maximize quality, and reduce cost.
Okay, thanks for the color. Appreciate it.
Andrew Carter with Stifel, your line is open.
Hey, thanks. Good morning. I wanted to ask, given the progress to date, pretty strong sales growth, plus-30%, you’ve got 40% gross margin, very narrow on your EBITDA loss and close to breakeven. What are the main impediments to getting there in the next two quarters? Belleville is coming online but you’re getting efficiencies there. You continue the rate of sales growth, you’ve got some higher margin products coming online. I’m a little surprised--and I know you walked a little bit away from it that it’s still predicated on store growth, but it seems like this would be a pretty achievable target just growing with the market in the next upcoming quarters.
Andrew, the certainty behind Hexo has never been higher, so your read, I think is accurate. We’ve been focused on reducing variability as we go forward and to get--to mature as an organization. We’re coming off of a seven-year explosive growth start-up, and as we put a ton of effort in putting top CPG executives in play, Hexo has really matured its planning process.
Yes, I agree with you. I think that our plan is more realistic than ever, and obviously there’s still some large caveats like COVID, which is still out there, so we’ve got to be careful with those types of things and plan very carefully but we’re putting health and safety first, which should mitigate some of that risk. Very confident about the future.
Great. Then second question, I believe the previous guidance at the high end had capex at $110 million for the year. Is that still the case, and I wanted to ask given the liquidity situation is much improved, are you going to accelerate any of your capital plans or is it still a very meaningful step-down coming next year?
Everything we’re doing is driving to revenue, Andrew, so meaningful step-down for sure. We’re really taking a philosophy on capex of making sure we get a good return on capital, so any new incremental project, I’m having the team present a full case and I’ve told them, don’t even bother presenting me something that doesn’t have a three-year payback. We’re targeting two years or better, and that’s really setting the foundation for more responsible spend and tying into that narrow and deep philosophy that we have at Hexo.
Thanks, I’ll pass it on.
Matt Bottomley with Canaccord, your line is open.
Good morning. Thanks for taking the question. Just wanted to clarify something on the value segment of the market and where Hexo looks to put its efforts in various categories. Sebastien, just wondering if you can comment on how this translates to your 2.0 offerings - obviously a lot of new edibles coming to market, [indiscernible] has been around now since January, so as you start ramping up some of these products, how do you view pricing or value segments there? It’s hard to tell just from looking at some of the provincial websites, but it does seem that a couple of these quote-unquote value priced edibles, some of them that are priced at significant haircuts to the overall average, seem to be gaining the most volumes, which makes sense as well. So are you going to have a similar philosophy in those products to start, or any sort of indication on what types of pricing points you’re going to be focused on in the initial rollout?
Yes, I’d invite everybody to think a little bit broader than just value and high end. I think the most critical piece to understand our Original Stash strategy is black market displacement, so when we think of a $4 gram, for example, in the context of the legal market that sounds like value. In the context of the illicit market, that’s just what people pay, so for a high quality gram, that’s really the mission of Original Stash.
That line extension, you’ve seen us take that into Hash, for example. Now, we happen to be the only product in hash today on a national scale, which is quite exciting, but we’ve priced Hash despite the fact we have no legal competitors to speak of, we are delivering value to consumers. We’ve priced Hash at the black market price, and that’s our philosophy surrounding everything we’re going to do under the Original Stash flagship.
Now, we’ll have some opportunities to do some fully disruptive premium things, so when we come up with 26% THC flower, for example, that we’re slotting into our Hexo Plus brand because that’s simply THC percentages that the black market can’t deliver today, at least from the tests we’re running.
There’s a lot of opportunity still for premium in these products. Again, when you think ready to drink beverages, a lot of opportunities there. I also want to make sure that in the long term, we’re offering consumers beverages that are familiar to them and that are in a segment that’s approachable. A few years out, I would love for somebody to be able to pick up a case of Truss Powered by Hexo cannabis beverages for $1 or $2 a can. I think that would be critical. For that to open up, though, we need the distribution to evolve where we can sell case quantity to really deliver that value in 2.0.
One follow-up, just on the beverages. I’ve heard for a number of producers out there that the government has allocated some crazy five-gram equivalent per 10 milligrams that go into a bottle, which is making it hard for consumers to buy 2-4s, let’s say, one day or something of these products. Is that something that is weighing on the potential penetration of these products, or is it just sort of noise in the interim?
No, no, you’re right. That’s certainly an impediment right now. The regulatory work--I mean, remember that Health Canada has been presented with brand-new legislation, first to legalize, first to introduce 2.0. Introducing--and they’re right at the intersection of food and cannabis, it’s a very complicated place to operate, so I think in that context we have to give them some leash to understand how to evolve the regulations in the right way.
The regulations today are not where they should be. There are still some inconsistencies in terms of concentration. To your point, if you walk into a store, you might be able to five ready to drink beverages. That doesn’t make a lot of sense if we’re looking at risk-based policy. The total amount of THC in those five drinks would be less than what you could buy in an equivalent extract, for example.
There is some harmonizing to do while putting public safety first, and I think those avenues are available. I think the industry association, I think Hexo have been pushing for those evolutions, and I know Health Canada is working hard on doing it, so that will come and it will help the market.
Thanks, and if I could just ask quickly, I know you’ve touched on it, just with respect to capital allocation. The $150 million dollars that you currently have right now, you’ve talked about certain elements that it might be applied to, but you can give sort of a larger view or a 30,000 foot view of how much of that is earmarked for interim opex burn, potentially funding Truss, other initiatives you’re doing, versus what might be considered, for lack of a better term, rainy day money?
Well, we’re certainly being efficient with our capital, so I don’t think the idea is to do any rainy day money. But in terms of specific breakdown, Matt, we’re not providing the capex-opex breakdown at this time.
Okay, thank you.
David Kideckel with AltaCorp Capital, your line is open.
Hi, good morning. Congratulations on your quarter. Just a couple of questions here. The first is on Truss. I’m just wondering, Sebastien, if you can give a little bit of color with respect to the timing of the rollout, and also is your intent here, just from a strategic perspective, to deploy beverages across Canada all at once, or are you looking more at a phased approach, maybe starting with your home province of Quebec?
Well, the interesting thing--I mean, Truss, although obviously we’re half of the partner there, Truss is its own company with its own management team, and so Quebec is an incredibly important market for Truss but they’re really looking at this as a national play.
With that being said, Truss is being very selective in where it goes for distribution and making sure that it has the right type of distribution deals in place. Obviously logistics are a lot more complicated with ready to drink beverages, and we’re leveraging Molson’s experience there.
We do expect to be in most of the nation when we launch, and the launch is coming soon. For a specific date, I’ll let Scott Cooper, the CEO of truss take that thunder in the next short while.
Okay, thank you. You made an interesting comment as well during your prepared remarks regarding Hexo really being a manufacturing type of organization but not forgetting your roots as being in agriculture. I’m just wondering what your thoughts are for the medium to long term. Should we still think of cultivation as being obviously key to really all cannabis companies, and if so, do you think altogether moving forward, is cultivation something that Hexo would likely rid itself from altogether?
So the interesting question, would we get rid of cultivation, theoretically if you weren’t good at it, yes, you’d want to jettison that business. But Hexo is one of the best in the country, if not the best, so in terms of cultivating we’re phenomenal at it. The quality is great, the cost is best-in-class, and we keep improving. Our THC yields, I’ve talked about it, but we’re now outputting 26% THC out of the greenhouse, so big kudos to my cultivation team. So in that context, no, absolutely I’m not getting rid of cultivation. We’re going to keep it because it’s a big driver of profitability.
I do think you’re on the right track, though, in thinking of cannabis companies not as a one-size-fits-all. I think you have cultivation companies, I think you have manufacturing companies, I think you have IP companies, and that’s why it’s so important for Hexo to be a top market share leader. That’s why it was so significant to move from number five to number four, and on our way to top two, is because we are a full service offering licensed producer. We have one of the most robust IP portfolios in the space as we’re invested in innovation. We’re one of the lowest cost producers on the cultivation side, and now with the Belleville asset, we’re possibly one of three or four companies that have the scale and manufacturing expertise to deliver true manufacturing.
We’re playing in all those--in those three segments. Manufacturing will start to take more and more importance as we go forward, and what’s really exciting about manufacturing is that it uncouples the value of the company from the value of or the scale of the cultivation. Where before all these companies were valued on, okay, you can grow 50 tons for example, so your value is X, with Belleville and our manufacturing, we can manufacture more products than we can grow, so what ends up happening is as prices continue to grow and as we see other competitors specialize in agriculture and cultivation, if they don’t have manufacturing, we’ll be able to provide that service for them and then we’ve just created upside revenue potential that’s beyond our cultivation ceiling.
Thank you, that’s helpful. If I can just ask one more question, going back to Original Stash, I’m just curious when you mentioned, Sebastien, you do have a high THC product that will enter the market, or might be in the market now, I’m going to assume just for this question that we can call it a premium high THC product, and if so, when you’re looking at customer preference here, or consumer preference when it comes to Original Stash being meant to really get rid of illicit market product altogether, when you introduce now a high THC product and also calling it Hexo Plus, I think you mentioned, are there any potential issues with consumers, how they’re thinking about Original Stash and a Hexo product versus a Hexo Plus high THC product, and any sort of challenges just for the consumer to integrate with, on the one hand, Original Stash being a lower quality type product compared to a higher THC product?
Yes, so a lot to unpack there, David - thanks. The Hexo Plus product has a brand promise of a minimum 20% THC. We noticed in market that consumers were asking and saying, we don’t want these blah THC ranges, and sometimes we don’t really know what we’re getting until we have the package in our hand, so that’s why we introduced Hexo Plus. There is not a gram in Hexo Plus that’s under 20%, and in fact most of them are going to be north of 25, 26%, as I’ve said, but there’s a brand promise there.
Now, that comes with a premium pricing scheme. On Original Stash, what you have to compare to is the true quality of illicit market, right? When we look at broad testing of illicit market, objective data, illicit product is coming in at 13 or 14% THC. Our Original Stash currently is sitting north of 16%, so it is incorrect to name it lower quality. It is much higher quality than what’s available on the black market, and of course care and control, any humidity, and of course the lack of pesticides, so you get all that added value.
The challenge is telling that to consumers because the illicit market has been telling people for years that they’re growing 35% THC product. That is not true, but the consumer does believe it today. Over time as we educate, I think there’s a lot of work for us and our provincial partners to get that message across to consumers, and as we do that, we’ll be more and more successful with our branding.
Thank you, that’s very helpful. That’s it for me.
Douglas Miehm with RBC Capital Markets, your line is open.
Thanks, good morning. I have two questions. Number one, as we look to 2.0 products and the growing importance in the market, can you maybe talk about vape pens? One other thing specifically I’d like you add in here is you were really the first--you had first mover advantage when we thought about a value market. Are you thinking along the same lines for vape pens or something like that?
Thanks Doug. First, super excited, we’ve got--our disposables are in market in Alberta, so we are currently at pilot scale on our vape manufacturing. We will at some point, I’m sure, take in our Belleville facility to do the--to flip the cost on its head and go to the next level. But more importantly from a quality perspective, our vapes have been extensively tested, no adverse reactions through our clinical trials, so we have actual data, so we’re very confident putting those in front of consumers. They are made from all-natural ingredients, so there is no extraneous chemicals or anything that might cause those adverse reactions, so we’re very, very happy.
Our innovation team has done a phenomenal job on the flavor profiles, so we’re getting rave reviews at the moment. We’ve actually managed to really deliver specific experiences with the mix of flavoralls and terpenes, so in our disposables--I mean, for example our Train Wreck product that’s a disposable vape that’s currently in Alberta, is coming back with reviews. People are calling it some of the strongest vapes they’ve ever tried, so we’re very, very happy with that quality. Now the question will be how do we scale that up from a manufacturing perspective.
I think it’s a completely different strategy with vape and Original Stash from approach to the market, because vape is a much more complex manufactured product. You also have a ton more upside once you automate, so it’s going to be exciting to see that one roll out.
Okay, that makes perfect sense. Second question just has to do with the scaling up to commercial levels on the beverage side. Can you comment on whether or not you’ve seen any lot to lot consistency or variability, I guess, and if you’re experiencing similar issues to what perhaps some of your competitors saw as they rolled out and were launching at scale?
Thanks for that. No, in fact--and this is why I’m so happy we partnered with Molson Coors, because if I had tried to do these beverages on my own, I would have had the same issues as my competitors. The Molson guys are--I mean, they’ve been doing beverages for 300 years. They came in and they installed a five parts per billion oxygen control system in our system, so we have now--we now know, and we’ve known for a while, that oxidation of cannabinoids is a problem for quality. There’s simply--there’s next to no oxygen in our system, which is phenomenal for quality and consistency. Our shelf stability is very strong. The flavorings that we’re using are very stable. We’re very, very pleased with the quality. I think we’ll leaders. We’ll need to see in market how the consumer responds, but certainly from a production standpoint the Bellville Truss beverage facility is the most advanced cannabis beverage facility I’ve seen on the planet.
Okay, great. Thanks very much, Sebastien.
Pablo Zuanic with Cantor Fitzgerald, your line is open.
Yes, good morning. A couple of questions. How should we think about this huge increase expected by the fall in outdoor cannabis cultivation? Is that going to affect the flower category in value or even pre-rolls, or is it just something that’s going to go to oil and extracts mostly? I’m just trying to think how that affects the category and different formats, and particularly the value segment for flower, or maybe not at all.
It’s been really interesting to take a look at some of the outdoor grow stuff. First, I don’t think anyone’s figured out how to do it profitably. If you look at the margin profiles of some of the outdoor growers, their gross margin is half of that of Hexo, so there’s some work to do just on the supply chain. That’s number one. It’s not ready to go.
Once it is ready to go, will it impact the flower market? I don’t think so. Consumers don’t want outdoor product really at any price. You’re also going to have a lot of quality issues with that product, so no, I don’t think it’s going to significantly impact the flower market.
To your point, how does it come into play with extraction? I think that’s something we need to keep a close eye on - does it displace hemp? That’s why it’s so significant for us to be installing massive extraction capacity ourselves at our Belleville facility, truly moving to being a manufacturing company. Hexo is not going to invest in outdoor - we’re not taking that risk, but in the case where it’s successful, we can become a net buyer of outdoor product, run it through our world-class extraction processes, and then feed our 2.0 offerings. For us, we’ll be agnostic whether we get those cannabinoids from an outdoor cannabis grower, an outdoor hemp grower, or a biosynthetic producer down the line. What’s important to Hexo is being able to manufacture great products, formulating IP-protected experiences, and having consumer market share.
One more. Just remind us what percentage of your sales came from the Quebec province, if you can disclose that, for the quarter, and also characterize how Quebec performed as a market post the March pantry loading in April, May, even June compared to other provinces. Apparently there were less restrictions so the market performed better, but just some more color there in terms of the last three months for Quebec versus the rest of the country.
Yes, Quebec is still a primary market. Over 80% of our sales were in Quebec this quarter because we’ve kept that as our top priority market, but that was also capacity constrained historically. That capacity constraint has now largely lifted now, so you’ll see us starting to roll out, as I mentioned, in other markets, but we’re being selective to make sure that if we do go into a market, we want to play in that top two position.
Yes, but can you comment in terms of how the market performed in the last two, three months versus the other markets? It sounds like it’s been a much stronger market with less restrictions than Ontario, BC and other provinces, or is that not necessarily true, not so different?
No, really the margin improvement has come through cost controls, so it’s really not--
Sebastien, I’m sorry - not the margins, but I’m talking about the market. What I’ve heard from other provinces is that because of the store shut downs and restrictions, Quebec has been a market that’s been better performing as there’s been no major shutdowns, compared to other provinces. I’m just trying to understand, it seems like--
Yes, sorry. Quebec published their numbers, right, so 47 tons shipped, and then you compare--and I think that’s the top market in Canada right now. I mean, Ontario has done a phenomenal job as well - they shipped 35 tons, but obviously if you adjust for population, I think Quebec is clearly doing--has made the right choices in terms of getting to the most amount of people.
Right. One last one, if I may. I ask this of course respectfully. With the two equity offerings in the last two months plus the bond conversion, your shareholders - you know, those that held the stock back in February, March were diluted by about 64%. That’s massive, but maybe that’s of course to raise capital and to survive in this industry, especially with all the opportunities that you have. But after that, and today in the call you are talking about making use of the ATM in the future, I think that you need to give more color in terms of how people should think about the further risk of dilution in the months ahead. Can you comment on that a bit more? I mean, you didn’t really exactly give the capex number, if it was 110 or 150, but I’m just trying to feel more comfortable that there’s no major dilution coming in the next few months.
Thanks, that’s it.
Thanks for that. I think what’s important, and I’ve said this for the last seven years, Hexo has set out long term to build a globally dominant cannabis player. Those companies will require over the long term billions of dollars of capital. Now, I think we can safely revise that type of thinking because we’ve learned so much and we’re learning how to get a lot more capital-light. Years ago, I threw out a number. If you wanted to build one of the top three global cannabis companies, it’d cost you $6 billion - that’s a number I threw out. I think the number is lower than that today because I think we’ve gotten a lot smarter in how we approach and a lot more capital light.
We’ve had some international sales now at Hexo that you’ll see roll out in the following months. You’ll see that show up in our revenue line. We’re doing those right from Canada with no assets installed, no employees installed internationally, so we’re getting a lot smarter.
With that in mind, when you look at the global cannabis opportunity, and let me scale it back to even Canada, the top three players in Canada will be splitting a $10 billion market here in the country. Now our share, the licensed producers share of that market is going to be $5 billion, right - take out excise tax, take out margin, so you’ve got three players splitting a $5 billion market. Give $1 billion of that market to other small players, right, the non-majors.
I’m playing to be a major player. If Hexo is successful, we will have a significant share of a $4 billion revenue stream. The dilution needs to be controlled, but the bet and making it to that top three will make that dilution irrelevant because the success will be resounding for long-term holders.
Of course, we’re in a hyper volatile market and I certainly wish we would not have had this global pandemic, which put us in a position where we raised at terms that were unfavorable, but you’ve seen us recover from that. We’re no longer doing unit deals, so you can be rest assured that that’s off the table. We now have our ATM launching with unbelievable volumes, so giving us access to capital as needed, and more importantly we’re moving towards that adjusted EBITDA positive, so there’s not an opex strain.
I’ve also talked about our capital prioritization. If we’re deploying capital at a 30 to 50% return in the future, the dilutive effect becomes additive, not dilutive. I’m very confident in that strategy.
Does that answer your question?
Our final question comes from the line of John Chu with Desjardins. Your line is open.
Hi, just one quick question. Previously you had mentioned the Belleville facility was to act as a facilitator to bring on new 500--or top new partners in the market from the CPG perspective.
Sorry John, did you finish your thought? I lost you at CPG perspective.
Oh, yes. I was just curious about how discussions are with new CPG partners, now that the Belleville facility is up and running and licensed.
Well, we haven’t [indiscernible] yet, but they’re all asking, which is super exciting. We’re still--our conversations are ongoing. Again, those are long, full conversations, very complex deals. I’m still at the table with major world-class companies and we’re still very excited about the potential. We’ve got now about 400,000 feet of manufacturing space that’s in a licensed facility, world-class cannabis center of excellence, right next to another Fortune 500, right next to Truss, all in the same building, next to Hexo operations. That’s available to those Fortune 500 partners, so we’ll be beginning towards probably sometime in the next couple of month for not only those potential Fortune 500 partners but also other partners, investors, etc, so looking forward to showcase that facility. Yes, for sure I think that’s going to have a positive impact in landing some partners.
There are no further questions at this time. I would now like to turn the call back over to our presenters for final remarks.
Thanks everybody. That’s all we have for today. Very excited about the quarter. Thanks again. Big thanks to the team, and look forward to talking to everybody in Q4.
This concludes today’s conference call. We thank you for your participation. You may now disconnect.